Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Haemophilia ; 27(1): e78-e87, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33215800

ABSTRACT

INTRODUCTION: Von Willebrand disease (VWD) is the most common inherited bleeding disorder with a prevalence of 0.1%, characterised by quantitative or functional deficiency of von Willebrand factor (VWF). VWD diagnosis is based on symptomology, biochemical and genetic tests, but limited laboratory resources and VWD heterogeneity still generate an important subdiagnosis gap worldwide and in our country. AIM: To identify the type and subtype of VWD in a cohort of patients with a history of excessive bleeding in Western Mexico. METHODS: This prospective cohort study from 2012 to 2019 included patients with mucocutaneous bleeding or abnormal laboratory tests. A standardised questionnaire and confirmatory tests were applied: FVIII:C, VWF activity, VWF antigen, and VWF multimeric analysis. RESULTS: Of the 297 patients recruited, 207 (69.7%) were excluded because their values exceeded 50% in VWF activity and VWF antigen. Of those 90 remaining, 54 (18.2%) had low VWF, and only 36 patients (12.1%) were diagnosed with VWD. Among them, 17 (47.2%) had quantitative deficiencies, of whom 14 were assigned as type 1 and 3 as type 3.The remaining 19 cases were diagnosed as type 2 (52.8%): type 2A and 2B were the most frequent with 6 and 7 cases respectively; 4 cases were possible type 2M and two suggestive of 2N, however, this was not confirmed. CONCLUSION: This study highlights the challenges of VWD diagnosis using a comprehensive panel of diagnostic tests which should extend to supplemental tests of VWF:CB, VWF:FVIIIB, and sequencing the VWD gene to confirm the results from the panel assays.


Subject(s)
von Willebrand Diseases , Hemorrhage , Humans , Mexico/epidemiology , Prospective Studies , von Willebrand Diseases/diagnosis , von Willebrand Diseases/epidemiology , von Willebrand Factor/genetics
2.
Am J Med Genet C Semin Med Genet ; 184(4): 939-954, 2020 12.
Article in English | MEDLINE | ID: mdl-33191626

ABSTRACT

Our 25 years of experience in carrier diagnosis of hemophilia A (HA) and B (HB) in Mexican population comprises linkage analysis of intragenic F8/F9 neutral variants along with, in severe HA (SHA), detection of F8 int22h and int1h inversions. In symptomatic carriers (SCs) we explored Lyonization to explain their symtomatology. From a DNA-Bank of 3,000 samples, intragenic restriction fragment length (RFLPs) and short tandem repeats (STRs) of F8/F9 genes were assessed by PCR-PAGE and GeneScan. In SHA patients, F8 inversions were detected by inverse shifting-PCR/diagnostic and complementary tests. In SCs, we evaluated hemorrhagic symptoms, clotting FVIII/FIX and X-chromosome inactivation (XCI) patterns were assessed by HUMARA assay and the search of XIST promoter pathogenic variants. Informativeness of linkage analysis for HA carrier diagnosis with RFLP's/STR's increased to 74% and reached 80% with five RFLPs for HB. Combined Inv22/Inv1 diagnosed 113 possible carriers, three de novo Inv22-1, and confirmed 45 mothers as obligate or sporadic carriers. Among 21 SCs, four showed extreme skewed XCI pattern (~80:20) but had normal karyotype and no C43G pathogenic variant in XIST promoter. Clotting FVIII/FIX correlated with the active X in leukocytes. Our data integrate the largest comprehensive research worldwide on the molecular diagnosis of HA and HB carriers in terms of the number of studied and diagnosed cases, in addition to the genetic analysis in SCs. Intragenic RFLPs and STRs of F8/F9 genes along with F8 int22h/int1h inversions in SHA emerge as optimal variants for molecular diagnosis in Mexican population. In counseling SCs, inheritance of skewed X-inactivation should be considered.


Subject(s)
Hemophilia A , Chromosome Inversion , Factor VIII/genetics , Genetic Testing , Hemophilia A/diagnosis , Hemophilia A/genetics , Humans , Polymerase Chain Reaction
3.
Blood Cells Mol Dis ; 83: 102423, 2020 07.
Article in English | MEDLINE | ID: mdl-32224444

ABSTRACT

INTRODUCTION: Molecular analysis in haemophilia is currently used in the diagnosis, treatment and prognosis of this disease. Hispanic populations in Latin America have been of interest to researchers due to the reportedly high prevalence of inhibitors in these patients. AIM: To perform next-generation sequencing (NGS) in a cohort of Mexican patients with HA and HB and correlate with clinical phenotypes. METHODS: Patients with Haemophilia A (HA) or haemophilia B (HB), were evaluated using NGS with an Ion AmpliSeq Custom Panel. Odds ratios (ORs) for associations between F8 variants and inhibitors were obtained. RESULTS: A total of 85 patients (60 with HA and 25 with HB) were included. Pathogenic variants in F8 were found in 93.3% of HA patients and in F9 in 96% of HB patients. Twelve novel potentially pathogenic variants were found. Inhibitors were observed in 20% of patients with severe HA. Four patients clinically diagnosed with HA were negative for F8 variants. CONCLUSION: Overall detection rate of pathogenic variants in F8 and F9 genes was 94.6%. We identified 12 non previously reported variants and pathogenic variants in other coagulation related genes. Molecular diagnosis of HA and HB permits better options for management, assessment and genetic counseling.


Subject(s)
Hemophilia A/genetics , Hemophilia B/genetics , Mutation , Cohort Studies , Factor VIII/chemistry , Factor VIII/genetics , Genetic Predisposition to Disease , Hemophilia A/diagnosis , Hemophilia A/epidemiology , Hemophilia B/diagnosis , Hemophilia B/epidemiology , High-Throughput Nucleotide Sequencing , Humans , Mexico/epidemiology , Models, Molecular
4.
Mol Genet Genomic Med ; 7(11): e979, 2019 11.
Article in English | MEDLINE | ID: mdl-31566926

ABSTRACT

BACKGROUND: The pathophysiology of hemophilic arthropathy is complex and not completely understood. In this study, we aimed to identify biomarkers that can affect the hemophilic arthropathy severity. METHODS: Fifty patients were analyzed for biomarker frequencies; in 37 patients, articular symptoms were evaluated based on the physical joint examination score, and in 18, it was based on magnetic resonance imaging. Eight polymorphisms, namely FV 1691G>A, FII 20210G>A, MTHFR 677C>T and 1298A>C, TNFα-308G>A and -238G>A, ACAN VNTR, and IL1RN*2-VNTR were identified. RESULTS: Patients with the MTHFR 677TT genotype showed a higher number of affected joints (1.83 ± 0.9 vs. 0.55 ± 0.7 for CC; p = .023), whereas those with the MTHFR 1298AC genotype exhibited higher effusion according to two radiologists (0.90 ± 0.31/1.20 ± 0.63 vs. 0.38 ± 0.52/0.50 ± 0.53 for AA genotype; p = .043/0.036, respectively). In addition, patients with the TNFα-308GA genotype had more subchondral cysts (0.75 ± 0.95 vs. 0.07 ± 0.26 for GG genotype; p = .041). CONCLUSIONS: The distribution of risk genotypes for MTHFR and TNFα-308GA suggests their association with clinical parameters of hemophilic arthropathy. Cohort studies are essential to verify these associations.


Subject(s)
Cartilage/pathology , Genetic Markers , Hemarthrosis/diagnosis , Hemophilia A/physiopathology , Inflammation/diagnosis , Adolescent , Cartilage/metabolism , Child , Child, Preschool , Female , Hemarthrosis/epidemiology , Hemarthrosis/genetics , Humans , Incidence , Infant , Infant, Newborn , Inflammation/epidemiology , Inflammation/genetics , Male , Mexico/epidemiology , Prognosis
5.
Blood Cells Mol Dis ; 71: 45-52, 2018 07.
Article in English | MEDLINE | ID: mdl-29544691

ABSTRACT

Intron-22 (Inv22) and intron-1 (Inv1) inversions account for approximately one half of all severe cases of hemophilia A (SHA) worldwide. Inhibitor development against exogenous factor VIII (FVIII) represents a major complication in HA. The causative F8 mutation is considered the most decisive factor conditioning inhibitor development. We aimed to investigate prevalence of Inv22 and Inv1 mutations, and its association as risk factors for developing inhibitors to FVIII. We investigated Inv22 and Inv1 in 255 SHA Mexican patients from 193 unrelated families using the inverse shifting-polymerase chain reaction (IS-PCR). We analyzed the association between inversions and inhibitor development via logistic regression introducing as covariates the populations, the inversions, F8-haplotypes and the age of patients at enrollment. Inv22 was found in 91/193 (47.2%: 38.9% exhibited Inv22-1 and 8.3% Inv22-2), and Inv1 in 2/193 (1.0%) independent families. Absolute inhibitor prevalence (IP) for Inv22 in unrelated patients was 15% (10-19). The cohorts and age of patients were independent predictors of inhibitor risk, but not inversions or haplotypes. Inversions presence in our population was associated to a moderate risk of developing inhibitors. Inv1 was found for the first time in two Mexican families. A relevant genetic component was observed by the strong concordance among brother-pairs.


Subject(s)
Blood Coagulation Factor Inhibitors/immunology , Chromosome Inversion , Factor VIII/genetics , Hemophilia A/genetics , Hemophilia A/immunology , Introns , Isoantibodies/immunology , Adolescent , Adult , Blood Coagulation Factor Inhibitors/blood , Child , Child, Preschool , Haplotypes , Hemophilia A/diagnosis , Hemophilia A/drug therapy , Humans , Infant , Isoantibodies/blood , Male , Middle Aged , Risk Assessment , Young Adult
6.
Thromb Res ; 136(6): 1291-8, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26493603

ABSTRACT

BACKGROUND: Thrombin generation assay (TGA) is useful as a global functional test for assessing bleeding or thrombotic risk and its modification with therapy. We investigated TGA to assess anticoagulation status compared with the international normalized ratio (INR) system in patients with primary thrombophilia receiving and not undergoing thromboprophylaxis. MATERIALS AND METHODS: We studied 50 patients with at least one thrombotic event and a confirmed diagnosis of inherited thrombophilia. Thrombin generation was measured in platelet-poor plasma by calibrated automated thrombography (CAT). RESULTS: Patients in optimal anticoagulation (INR: 2.0-3.0) showed an endogenous thrombin potential (ETP) of 14-56% of normal and a peak of 18-55% of normal. A significant inverse relationship between INR and thrombin generation parameters (ETP, peak and velocity index) and a linear correlation for lag time was found in patients treated with vitamin-K antagonists (VKA). Receiver-operating characteristics (ROC) analysis showed that the optimal cutoff for ETP was 1600.2 nM · min (111.6% of normal, with a sensitivity of 96.6% and a specificity of 92.9%) and for the peak was 298.3 nM (112.1% of normal, with a sensitivity of 96.4% and a specificity of 100%). According to this analysis, ETP was able to identify patients with increased thrombotic and hemorrhagic risk, correlating with severe clinical complications. CONCLUSION: TGA showed excellent sensitivity and specificity for assessing anticoagulation status in patients with primary thrombophilia receiving VKA, with significant advantages with regard to INR. Clinical data strongly support ETP as a valuable indicator of thrombotic or hemorrhagic risk in patients receiving or not receiving thromboprophylaxis.


Subject(s)
Thrombin/chemistry , Thrombophilia/genetics , Thrombophilia/prevention & control , Adult , Anticoagulants/chemistry , Calibration , Cohort Studies , Female , Healthy Volunteers , Hemorrhage/complications , Heterozygote , Humans , International Normalized Ratio , Male , Middle Aged , Partial Thromboplastin Time , Prothrombin Time , ROC Curve , Risk Factors , Thrombelastography , Thrombosis/complications , Vitamin K/antagonists & inhibitors , Young Adult
7.
Clin Biochem ; 48(7-8): 538-41, 2015 May.
Article in English | MEDLINE | ID: mdl-25617665

ABSTRACT

OBJECTIVE: Here we aimed to investigate the in vitro effects of three analgesic-antipyretic drugs frequently used in clinical practice in Mexico - acetaminophen (AAP), aspirin (ASA) and metamizole (MMZ) - on serum measurements of glucose, urea, and creatinine. DESIGN AND METHODS: Each analyte was measured in a base-serum pool spiked with the drugs at subtherapeutic, therapeutic, and toxic doses. Serum glucose and urea were measured using the hexokinase/G-6PDH and urease/GLDH kinetic assays, respectively. Serum creatinine (SCr) was measured with a Jaffe procedure based on the alkaline-picrate reaction and with an enzymatic dry-chemistry system. Measurements were carried out in IL-Monarch and Vitros DT60-II analyzers, respectively. Data were analyzed by the difference-paired interference test and by ANOVA. RESULTS: By the kinetic Jaffe/Monarch procedure, we found positive interference by the drugs on the SCr measurements and by only ASA for urea measurement. For creatinine measurements, the total errors (TEs) were 22-51%, 18-105%, and 15-26% for AAP, ASA, and MMZ respectively, while for urea measurement the TE was 16-21% for ASA. A negative interference by MMZ on SCr (TE=-47%), but no-interference for AAP or ASA, were found via the enzymatic/DT60-II system. CONCLUSIONS: In vitro positive interference induced by AAP, ASA, and MMZ (via the alkaline-picrate reaction), or negative interference by MMZ (via a dry-chemistry system), on the SCr measurements highlights the importance of investigating all possible sources of variation that may alter the accuracy of the laboratory tests, in order to provide useful results for making medical decisions for optimal patient care.


Subject(s)
Acetaminophen/chemistry , Aspirin/chemistry , Blood Glucose/analysis , Creatinine/blood , Dipyrone/chemistry , Urea/blood , Biological Assay/standards , Blood Glucose/chemistry , Creatinine/chemistry , Humans , Reproducibility of Results , Urea/chemistry
8.
Rev Med Inst Mex Seguro Soc ; 47(2): 193-8, 2009.
Article in Spanish | MEDLINE | ID: mdl-19744390

ABSTRACT

OBJECTIVE: to show clinical and therapeutic findings in patients with diagnosis of acute megakaryoblastic leukemia (AML). METHODS: twenty four patients with diagnosis AML was carried out. Clinical, laboratory survey results and treatment response were studied. Nineteen patients had primary form and five secondary, attended during a period of eight years. The diagnosis was established by a highly clinical suspicious, with immunophenotype cytometry flow or/and bone biopsy with immunohistochemistry study which proves definitely AML. RESULTS: Fourteen were women, the median age was 43 years, 18 were treated with antineoplasic agents, ten obtained response, six complete and four partial. The response may improve with schemes with high dose of cytosine arabinoside. CONCLUSIONS: our results with the treatment showed that 27 % patients are alive under maintenance treatment long 18 months. The allogeneic bone marrow transplant seems to be one more option in long term.


Subject(s)
Leukemia, Megakaryoblastic, Acute/diagnosis , Leukemia, Megakaryoblastic, Acute/therapy , Adolescent , Adult , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
9.
Am J Hematol ; 82(4): 283-7, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17211847

ABSTRACT

Hemophilia A (HA) is one of the most common inherited bleeding disorders caused by FVIII gene mutations. Inversion of intron 22 (inv22) originates 50% of cases of severe HA and is a major risk factor for inhibitor development. Inversion of intron 1 (inv1) has been reported to occur in 2-3% of severe HA patients. We studied both inversions to determine their frequencies in Mexican patients with severe HA and to compare these data with other HA populations. The inv22 was evaluated as a risk factor for FVIII inhibitor development in severe HA patients. We studied 44 patients from 31 severe HA families for the detection of inv22 and 94 patients from 65 families to detect inv1. We used the subcycling long-distance PCR to detect inv22 and rapid PCR in duplex reactions to detect inv1. We found a frequency of 45% for the inv22 and no inv1-positive patients (0%). These frequencies were not statistically different from other populations, although haplotype analyses of FVIII gene and telomeric regions should be incorporated to explore population-specific variation of inv1 frequencies. Inv22-positive patients showed 1.88X higher risk for developing inhibitors with respect to patients carrying other severe mutations; however, this OR value was not significant. Our findings confirm inv22 as a hot-spot for severe HA and evidence the low frequency of inv1 in a Mexican population. The non-significant risk for developing inhibitors among inv22-positive patients agrees with the variety of genetic and non-genetic factors involved in such a complication.


Subject(s)
Chromosome Inversion/genetics , Factor VIII/genetics , Hemophilia A/genetics , Introns/genetics , Isoantibodies/adverse effects , Chromosome Inversion/statistics & numerical data , Cohort Studies , Cross-Sectional Studies , Factor VIII/immunology , Gene Frequency , Hemophilia A/therapy , Humans , Isoantibodies/immunology , Mexico , Odds Ratio
10.
Ginecol. obstet. Méx ; 66(11): 456-61, nov. 1998. ilus, tab
Article in Spanish | LILACS | ID: lil-232597

ABSTRACT

La cuantificación del fragmento 1+2 de protrombina se hizo por método inmunoenzimático en 75 mujeres (55 embarazas y 20 post-cesárea) y el dímero D por determinación semicuantitativa mediante aglutinación en placa en 97 casos (77 embarazadas y 20 post-cesárea). El fragmento 1+2 se encontró significativamente elevado en el 85 por ciento de los casos, sin embargo no mostró tener utilidad predictiva de enfermedad tromboembólica. La cuantificación del dímero D no fue detectada en 40 casos, en 33 fluctuó entre 500 y 1000 ng/ml y en los 24 restantes fue superior a los 2000 ng/ml. Valores mayores a 1000 ng/ml fueron observados en el 78 por ciento de las que tenían antecedentes de enfermedad tromboembólica, en las de cesárea 60 por ciento, en el 37 por ciento de las hipertensas y en 23 por ciento de las diabéticas. El dímero D que en el 59 por ciento de las embarazadas y puérperas registró valores superiores a 500 ng/ml tiene valor predictivo, ya que en 24 casos que cursaban con más de 2000 ng/ml, el 25 por ciento presentaron ETE y/o anormalidades de la coagulación sugestivos de actividad trombótica. Estos hallazgos no fueron observados en la 73 mujeres evaluadas que tuvieron dD negativo o < de 1000 ng/ml


Subject(s)
Humans , Female , Pregnancy , Peptide Fragments/analysis , Biomarkers/blood , Predictive Value of Tests , Pregnancy Complications, Cardiovascular/blood , Fibrin Fibrinogen Degradation Products/analysis , Prothrombin/analysis , Puerperal Disorders/blood , Risk Factors , Thrombosis/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...